Page last updated: 2024-10-16

carbamates and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

carbamates has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bright, SA1
Greene, LM1
Greene, TF1
Campiani, G1
Butini, S1
Brindisi, M1
Lawler, M1
Meegan, MJ1
Williams, DC1
Zisterer, DM1

Other Studies

1 other study available for carbamates and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Biochemical pharmacology, 2009, Feb-01, Volume: 77, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Carbamates; Cell Line, Tumor; Down-

2009